Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):114-20. doi: 10.1016/s0360-3016(03)00077-4.

Abstract

Purpose: To evaluate the effects of chemoradiation on objective tests of pulmonary function.

Materials and methods: One hundred lung cancer patients treated in five protocols between 1992 and 2000 with combinations of thoracic radiotherapy (RT) and chemotherapy were evaluated with pre- and post-RT pulmonary function tests. The pulmonary function tests were analyzed for changes in measures of obstruction (forced expiratory volume in 1 s per unit of vital capacity [FEV(1)/VC]), restriction (total lung capacity [TLC]), and diffusing capacity (diffusing capacity for carbon monoxide [DLCO]). The use and timing of chemotherapy and RT, as well as patient, tumor, and treatment factors, were evaluated using univariate and multivariate analyses.

Results: No treatment or patient factors were significantly associated with changes in FEV(1)/VC. Chemotherapy with RT, compared with RT alone, was associated with a lower post-RT TLC (92% vs. 107%, p = 0.002). Nodal status (N2-N3 vs. N1), tumor location (central vs. peripheral), use of >/=6 treatment fields, and tumor volume >/=100 cm(3) were also associated with a significantly lower post-RT TLC. On univariate analysis, the use of any chemotherapy (p = 0.029) and the use of concurrent vs. sequential chemotherapy (p = 0.028) were predictive of a lower post-RT DLCO. Patient age >/=60 years, nodal status (N2-N3 vs. N0-N1), tumor volume >/=100 cm(3), tumor location (central vs. peripheral), and use of >/=6 treatment fields were also associated with a significantly lower post-RT DLCO. The fractional volume of irradiated normal lung correlated with the decrease in DLCO (p <0.001), with a 1.3% DLCO decline for each 1% of total lung volume that received >20 Gy.

Conclusions: The addition of chemotherapy to RT significantly exacerbates the post-RT decrease in TLC and DLCO. The greatest decrease in DLCO occurs in patients treated with concurrent chemoradiation.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carbon Dioxide / metabolism
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / physiopathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Cisplatin / administration & dosage
  • Cisplatin / pharmacology
  • Combined Modality Therapy
  • Etoposide / administration & dosage
  • Etoposide / pharmacology
  • Female
  • Forced Expiratory Volume
  • Humans
  • Lung / drug effects
  • Lung / physiopathology
  • Lung / radiation effects*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / physiopathology
  • Lung Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Pulmonary Diffusing Capacity
  • Radioisotope Teletherapy / adverse effects*
  • Respiratory Function Tests
  • Retrospective Studies
  • Total Lung Capacity
  • Vinblastine / administration & dosage
  • Vinblastine / pharmacology

Substances

  • Carbon Dioxide
  • Vinblastine
  • Etoposide
  • Cisplatin